Mega-cap Monday: Why This 1 Pharma Stock is a Buy at 52-Week Lows

Dear Bottom Line Investor,

Welcome to Mega-cap Monday!

This week we’re going to be trying something different where each day we follow a certain stock market theme. 

Today happens to be mega-cap Monday. Because, while we prefer smaller companies due to their potential to be misvalued by the market, there’s no denying that good values can be found even in the biggest of companies sometimes. 

And with that, we’re going to take a quick look at a stock we’ve all heard of: Pfizer (PFE).

Despite a steep drop from its 52-week high, Pfizer's strong dividend yield and strategic shifts toward high-potential sectors like oncology make it an attractive option for investors seeking stability and growth.

By the numbers:

• Dividend Yield: Around 6%, significantly higher than the industry average, offers investors a stable return in volatile markets.

• Stock Dip: At around $25, shares have fallen about 30% over the past year and 60% from their 2021 peak, primarily due to declines in COVID-19 product sales.

Pfizer's strategic response to the dwindling demand for its COVID-19 treatments includes:

• Pivoting Focus: Emphasizing oncology, including a $43 billion acquisition of cancer specialist Seagen.

• Innovating: Several new drug approvals expected to drive future growth.

With an acute awareness of the ephemeral nature of the COVID-19 revenue surge, Pfizer has skillfully redirected its focus towards burgeoning business areas.

This strategic shift is underscored by its acquisition of cancer treatment pioneer Seagen for $43 billion, a move that substantially enhances Pfizer's oncology portfolio by integrating 60 new programs across a variety of therapeutic modalities. This acquisition not only bolsters Pfizer’s position in oncology but also sets the stage for significant revenue contributions, with multiple potential blockbuster products anticipated by 2030.

Moreover, Pfizer’s commitment to innovation is evident in its recent approvals for new medications, poised to drive future revenue growth. This proactive approach in expanding its pharmaceutical offerings positions Pfizer for robust top-line growth, reigniting its status as a growth-oriented investment.

Pfizer’s current valuation, when viewed against Pfizer’s strong dividend yield and new growth initiatives, offers an attractive entry point for long-term investors.

Also, if you’re interested in taking the leap towards taking your career to the next level we recommend checking out…